VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
The company's BiTAC platforms represent a novel approach to cancer therapy, combining bispecific antibody technology with targeted delivery mechanisms. The BiTAC-ADC platform enables tumor-restricted activation of antibody-drug conjugates, potentially reducing systemic toxicity while enhancing therapeutic efficacy. The BiTAC-TCE platform focuses on bispecific T cell engagers designed to recruit immune cells specifically to tumor sites.
These developments are significant as they address key challenges in oncology, such as off-target effects and limited efficacy in solid tumors. By leveraging these platforms, VERAXA aims to expand the therapeutic window for cancer treatments. The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a renowned institution in life sciences research.
For more details, visit https://ibn.fm/1je4A. Additional updates are available in the company's newsroom at http://ibn.fm/VRXA.
